Erratum (DOI:10.1016/j.arcmed.2006.02.007);In Vitro Antiproliferative Effects of Neuroleptics, Antimycotics and Antibiotics on the Human Pathogens Acanthamoeba polyphaga and Naegleria fowleri

Archives of Medical Research

Volumn 37, Issue 6, 2006, Pages 723-729

  Ondarza, Raúl N ^a,b,c   Iturbe, Angelica ^a   Hernández, Eva ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Acanthamoeba polyphaga; Antibiotics; Antimycotics; Antiparasitic agents; Naegleria fowleri; Neuroleptics

Indexed keywords

AMPHOTERICIN B; ANTIAMEBIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CHLORPROMAZINE; KETOCONAZOLE; MEPACRINE; METRONIDAZOLE; MICONAZOLE; NEUROLEPTIC AGENT; PENTAMIDINE; RIFAMPICIN; TRIFLUOPERAZINE;

ACANTHAMOEBA; ACANTHAMOEBA POLYPHAGA; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NAEGLERIA FOWLERI; NONHUMAN; REPRODUCIBILITY; TROPHOZOITE;

EID: 33745653270     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.08.001     Document Type: Erratum

References (15)

1. Ficker L., Seal D., Warhurst D., and Wright P. Acanthamoeba keratitis-resistance to medical therapy. Eye 4 Pt6 (1990) 835-838
2. Hargrave S.L., McCulley J.P., and Husseini Z. Results of a trial of combined propamidine isethionate and neomycin therapy for Acanthamoeba keratitis. Brolene Study Group. Ophthalmology 106 (1999) 952-957
3. Seal D.V., Hay J., and Kirkness C.M. Chlorhexidine or polyhexamethylene biguanide for Acanthamoeba keratitis. Lancet 345 8942 (1995) 136
4. John D.T. Opportunistically pathogenic free-living amebae. In: Kreier J.P., and Baker J.R. (Eds). Parasitic Protozoa. 2nd ed. (1993), Academic Press, San Diego 143-246
5. Fahey R.C., Newton G.L., Arrick B., Overdank-Bogart T., and Aley S.B. Entamoeba histolytica: a eukaryote without glutathione metabolism. Science 224 (1984) 70-72
6. Ondarza R.N., Hernandez E., Iturbe A., and Hurtado G. Inhibitory and lytic effects of phenothiazine derivatives and related tricyclic neuroleptic compounds, on Entamoeba histolytica HK9 and HM1 trophozoites. Biotechnol Appl Biochem 32 Pt 1 (2000) 61-67
7. Ondarza R.N., Iturbe A., Hernandez E., Tamayo E.M., and Hurtado G. In vivo inhibition of reduced thiol compounds from Entamoeba histolytica HK9 by phenothiazines and related tricyclic drugs. Arch Med Res 31 4 (2000) S12-S16
8. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Twelfth Informational Supplement. Wayne PA: NCCLS, 2002;22(1). Document M100-S12.
9. Schuster F.L., and Mandel N. Phenothiazine compounds inhibit in vitro growth of pathogenic free-living amoebae. Antimicrob Agents Chemother 25 1 (1984) 109-112
10. Goswick S.M., and Brenner G.M. Activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother 47 2 (2003) 524-528
11. Goswick S.M., and Brenner G.M. Activities of therapeutic agents against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. J. Parasitol 89 4 (2003) 837-842
12. Schuster F.L., and Visvesvara G.S. Amebic encephalitides and amebic keratitis caused by pathogenic and opportunistic free-living amebas. Curr Treat Options Infect Dis 5 (2003) 273-282
13. Mattana A., Biancu M.G., Alberti L., Accardo A., Delogu G., Fiori P.L., et al. In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii. Antimicrob Agents Chemother 48 (2004) 4520-4527
14. Duma J.R., and Finley R. In vitro susceptibility of pathogenic Naegleria and Acanthamoeba to a variety of therapeutic agents. Antimicrob Agents Chemother 10 (1976) 370-376
15. Vargas-Zepeda J., Gomez-Alcala A.V., Vasquez-Morales J.A., Licea-Amaya L., De Jonckheere J.F., and Lares-Villa F. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch Med Res 36 1 (2005) 83-86